Drug intelligence / Profile preview

HS-20117 + platinum-containing chemotherapy

Development stage: Unknown
Lead developer: Hansoh Pharmaceutical Group
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

HS-20117 + platinum-containing chemotherapy is a combination therapy consisting of HS-20117 (a fully-human EGFR-MET immunoglobulin G1-like bispecific antibody) and platinum-based chemotherapy drugs. HS-20117 works by specifically inhibiting the growth and survival of tumors through targeting EGFR and c-MET pathways. This combination is being investigated for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) with EGFR mutations.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)DNA

Beyond the preview

Go deeper on HS-20117 + platinum-containing chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-20117 + platinum-containing chemotherapy.

Explore the full profile